Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does clopidogrel provide additional benefit to aspirin and fibrinolytic therapy in patients after STEMI?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 500–501 (2005)Cite this article

boxed-textSabatine MS et al. for the CLARITY-TIMI 28 Investigators (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179–1189

Adding clopidogrel to standard pharmacotherapy in patients under 75 years old with STEMI improves vessel patency and myocardial flow in the infarct-related artery, without increasing bleeding risk

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither in among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360

  2. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

  3. Gibson CM et al. (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101: 125–130

    Article  CAS  Google Scholar 

  4. Schroder R (2004) Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110: e506–e510

    Article  Google Scholar 

  5. Steinhubl SR et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288: 2411–2420

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. an Assistant Professor in the department of Medicine at McMaster University, Hamilton, Ontario, Canada

    Nicholas Valettas

  2. an Interventional Cardiologist at Hamilton Health Sciences, Hamilton, Ontario, Canada

    Nicholas Valettas

Authors
  1. Nicholas Valettas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas Valettas.

Ethics declarations

Competing interests

N Valettas has received honoraria from Bristol-Myers Squibb, the manufacturers of clopidogrel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valettas, N. Does clopidogrel provide additional benefit to aspirin and fibrinolytic therapy in patients after STEMI?. Nat Rev Cardiol 2, 500–501 (2005). https://doi.org/10.1038/ncpcardio0293

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0293

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing